# An Active and Placebo-Controlled Study of Brazikumab in Participants With Moderately to Severely Active Crohn's Disease

> **NCT03759288** · PHASE2,PHASE3 · TERMINATED · sponsor: **AstraZeneca** · enrollment: 89 (actual)

## Conditions studied

- Crohn's Disease
- IBD

## Interventions

- **DRUG:** Brazikumab low dose
- **DRUG:** Brazikumab high dose
- **DRUG:** Humira®
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03759288
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-12-07
- **Primary completion:** 2023-10-18
- **Final completion:** 2023-10-18
- **Target enrollment:** 89 (ACTUAL)
- **Why stopped:** Strategic decision to discontinue the development of brazikumab in inflammatory bowel disease.
- **Last updated:** 2023-11-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03759288

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03759288, "An Active and Placebo-Controlled Study of Brazikumab in Participants With Moderately to Severely Active Crohn's Disease". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT03759288. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*